Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
US11896663B2 · kind B2 · utility
0Cited by
13References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 3, 2021 |
| Grant date | Feb 13, 2024 |
| Priority date | — |
| Expiry date | Oct 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.